Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Diagnostic Blood Test Developed for Fibromyalgia

By Labmedica International staff writers
Posted on 17 Apr 2013
Print article
Cytokine-producing activity of immune cells of fibromyalgia (FM) patients has led to the development of a commercial blood test.

The very real biological condition of FM takes an average of three to five years for someone with the illness to get an accurate diagnosis as hitherto there was no diagnostic blood test to definitively confirm the disorder.

The blood test was developed in conjunction with a study that identified unique immunologic patterns in fibromyalgia patients. Scientists at the University of Illinois at Chicago (UIC; IL USA) measured plasma cytokine levels in a group of 110 patients with a diagnosis of FM and determined responses to mitogen challenges of their peripheral blood mononuclear cells (PBMC). The cytokine levels of these patients were then compared with those in a group of 91 matched healthy controls.

A custom panel of antibody-conjugated beads for measuring eight human cytokines (BioRad Laboratories; Hercules, CA, USA) was used in the assay. The investigators that cytokine levels of stimulated PBMC cultures of healthy control subjects were significantly increased as compared to matched nonstimulated PBMC cultures. In contrast, the concentrations of most cytokines were lower in stimulated samples from patients with FM compared to controls.

The FM Test is the first test to objectively diagnose fibromyalgia via a simple blood test, with results usually available in one week or less. The FM Test was developed by EpicGenetics (Santa Monica, CA, USA), and will cost USD 744. The FM test is a multi-biomarker-based assay, which comprises immune system white blood cell chemokine and cytokine patterns. Patients with fibromyalgia have a significantly dysregulated pattern regarding these proteins. Test results are based upon a 1-100 scoring system, with fibromyalgia patients having scores of 50 and above. The FM Test is more than 93% sensitive and by comparison, the rheumatoid arthritis blood test is only 65% sensitive.

Bruce S. Gillis, MD, MPH, the founder of EpicGenetics, said, “The result was the discovery of a major set of differences in cell-mediated immunity in the fibromyalgia group versus the healthy patient, and this discovery was opposite to what was anticipated. Specifically, while fibromyalgia patients are often considered to be ‘hyper/overactive responders,’ we identified that the fibromyalgia patients had a depressed and dysregulated immune system.” The original study the test was based on was published on December 17, 2012, in the journal BMC Clinical Pathology.

Related Links:

University of Illinois at Chicago
BioRad Laboratories
EpicGenetics




Print article

Channels

Clinical Chemistry

view channel
Image: Dried blood spots are used to screen newborns for a number of rare inherited conditions. A new dried blood spot screening test has been developed for Niemann-Pick type C, a rare neurodegenerative condition that usually is not diagnosed until after damage to brain cells has begun (Photo courtesy of Washington University School of Medicine).

Newborn Screening Test Developed For Deadly Neurological Disorder

A newborn screening test has been introduced that identifies infants with Niemann-Pick disease type C, an often fatal condition in which cholesterol builds up and eventually destroys brain cells.... Read more

Genetic Tests

view channel
Image: The BioMek FXP automation workstation (Photo courtesy of Beckman Coulter).

Innovative Gene Testing Technology Finds Cancer Risks

A new method has been developed for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate,... Read more

Pathology

view channel
Image: A photomicrograph of an abnormal Pap smear showing changes consistent with Human Papilloma Virus (HPV) and Mild Dysplasia. Note the irregular perinuclear cytoplasmic clearing, which is the key characteristic of identifying HPV visually on a Pap smear (Photo courtesy of Dr. Cynthia D Booth, MD).

Combining Two Diagnostic Tests Drastically Reduces Cancer Miss Rates

The Papanicolaou (Pap) test is recommended for women between 21 and 65 years old as a screening test for cervical cancer. Women 30 and older who are negative on co-testing may wait as long as five years... Read more

Lab Tech.

view channel
Image: Candida albicans growing on Sabouraud agar (Photo courtesy of Dr. William Kaplan / CDC).

Chemical Sensor Rapidly Detects Fungal Infections

An elevated concentration of D-arabitol, a simple sugar alcohol, in urine, especially compared to that of L-arabitol or creatinine, is indicative of a fungal infection, which can become deadly.... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.